Analyst Price Target is GBX 205.30
▲ +32.45% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Sourcebio International in the last 3 months. The average price target is GBX 205.30, with a high forecast of GBX 205.30 and a low forecast of GBX 205.30. The average price target represents a 32.45% upside from the last price of GBX 155.
Current Consensus is
The current consensus among 1 investment analysts is to buy stock in Sourcebio International.
Sourcebio International Plc, together with its subsidiaries, provides various laboratory services and products to clients in the healthcare, clinical, life science research, and biopharma industries in the United Kingdom, Europe, and the United States. The company's services cover histopathology reporting and human tissue testing services; genomics services to pharmaceuticals, biotechnology, life science, and academic markets; stability storage solutions; and COVID-19 antigen PCR testing services. It also manufactures reagents and kits for the blood group serology, blood banking, and tissue banking sectors; and engages in life science research activities, which cover antibodies, clones, cell culture reagents and assays, protein biology, laboratory essentials, and others. Sourcebio International Plc was incorporated in 2016 and is headquartered in Nottingham, the United Kingdom.